Genmab A/S (GMAB) Competitors

Genmab A/S (NASDAQ:GMAB) and Takeda Pharmaceutical (NYSE:TAK) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.

Which has preferable earnings and valuation, GMAB or TAK?

Genmab A/S has higher earnings, but lower revenue than Takeda Pharmaceutical. Genmab A/S is trading at a lower price-to-earnings ratio than Takeda Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$21.53B	0.59	$1.14B	$1.74	11.10
Takeda Pharmaceutical	$4.58T	0.01	$994.06M	$0.40	35.73

Which has more volatility & risk, GMAB or TAK?

Genmab A/S has a beta of 1.07, meaning that its stock price is 7% more volatile than the S&P 500. Comparatively, Takeda Pharmaceutical has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500.

Do insiders and institutionals believe in GMAB or TAK?

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by insiders. Comparatively, 0.0% of Takeda Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Is GMAB or TAK more profitable?

Genmab A/S has a net margin of 36.30% compared to Takeda Pharmaceutical's net margin of 4.53%. Genmab A/S's return on equity of 16.78% beat Takeda Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	36.30%	16.78%	13.79%
Takeda Pharmaceutical	4.53%	9.39%	4.53%

Do analysts rate GMAB or TAK?

Genmab A/S presently has a consensus price target of $39.17, suggesting a potential upside of 102.73%. Given Genmab A/S's higher possible upside, equities analysts clearly believe Genmab A/S is more favorable than Takeda Pharmaceutical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Takeda Pharmaceutical	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Does the media favor GMAB or TAK?

In the previous week, Genmab A/S had 11 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 18 mentions for Genmab A/S and 7 mentions for Takeda Pharmaceutical. Genmab A/S's average media sentiment score of 0.91 beat Takeda Pharmaceutical's score of 0.48 indicating that Genmab A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	6 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive
Takeda Pharmaceutical	2 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Does the MarketBeat Community prefer GMAB or TAK?

Genmab A/S received 66 more outperform votes than Takeda Pharmaceutical when rated by MarketBeat users. Likewise, 63.02% of users gave Genmab A/S an outperform vote while only 57.06% of users gave Takeda Pharmaceutical an outperform vote.

Company	Underperform	Outperform
Genmab A/S	Outperform Votes 167 63.02%	Underperform Votes 98 36.98%
Takeda Pharmaceutical	Outperform Votes 101 57.06%	Underperform Votes 76 42.94%

Summary

Genmab A/S beats Takeda Pharmaceutical on 15 of the 19 factors compared between the two stocks.